MRK: One big hit amongst smaller approvable assets

MRK: We examine in detail, the prospects of five median term Merck pipeline assets, over the next 6 years and find that there are good prospects for securing regulatory approval for at least 4 out of 5 assets, achieving an aggregate of $10bn of incremental sales from the late 2020s; half coming from best in class data in pulmonary hypertension, with less differentiated, although approvable assets making up the rest

MRK